LACTOLOGY FOUNDATION

Fidaxomicin (ATC A07AA12) is a minimally absorbed, gut‑selective macrocyclic antibiotic used orally for Clostridioides difficile infection (CDI), with very low systemic exposure and therefore a low theoretical transfer into breast milk. Direct lactation data are lacking, so use during breastfeeding is generally considered probably low‑risk but should be individualized, especially in newborn or preterm infants.

Pharmacological class and indications

Fidaxomicin is a narrow‑spectrum, bactericidal, macrocyclic antibiotic classified in ATC subgroup A07AA “Intestinal antibiotics,” with a primary indication for treatment of C. difficile–associated diarrhea (CDAD) in adults and children. It is favored in CDI because of targeted activity against C. difficile, limited effect on normal gut flora, and reduced recurrence rates compared with some standard therapies.

Mechanism of action

Fidaxomicin inhibits the sigma‑dependent initiation of bacterial RNA synthesis by binding to the DNA‑dependent RNA polymerase of gram‑positive organisms, resulting in inhibition of transcription and cell death of susceptible strains. Its spectrum is highly selective for C. difficile, with minimal activity against many commensal gut bacteria, helping preserve the intestinal microbiota compared with broader‑spectrum agents.

Pharmacokinetics relevant to lactation

After oral administration, fidaxomicin and its active metabolite OP‑1118 show minimal systemic absorption, with plasma concentrations in the low ng/mL range even in patients with active C. difficile colitis. The drug is largely confined to the gastrointestinal lumen, reaching very high fecal concentrations, while most of the absorbed fraction is excreted via the biliary route; the minimal maternal plasma levels suggest that transfer into breast milk, if any, should be extremely low.

Maternal toxicity and adverse effects

Fidaxomicin is generally well tolerated, with the most common adverse reactions including nausea, vomiting, abdominal pain, gastrointestinal hemorrhage, anemia, and hypersensitivity reactions such as rash or pruritus. Serious systemic toxicity is uncommon due to limited systemic exposure, but clinicians should be alert for rare hypersensitivity or anaphylactic reactions in treated adults, as described in product information.

Excretion into breast milk

No quantitative data are available on fidaxomicin or OP‑1118 concentrations in human milk. Lactation risk summaries from regulatory and expert sources state that it is unknown whether fidaxomicin is excreted in breast milk, but emphasize that, because the drug is poorly absorbed orally, it is unlikely to reach the bloodstream of the breastfed infant in meaningful amounts.

Reported effects in breastfed infants

There are no published clinical reports describing adverse effects in breastfed infants exposed to fidaxomicin through human milk. Given the low anticipated milk transfer and poor oral absorption in the infant, systemic toxicity appears unlikely; theoretical concerns relate mainly to potential local effects on the infant’s intestinal microbiota, as with other antibiotics, but this has not been documented for fidaxomicin.

Impact on lactation and breast milk

There is no evidence that fidaxomicin alters prolactin levels, milk production, or the nutritional composition of breast milk. General reviews of antibiotics in breastfeeding indicate that most agents, particularly those with poor oral bioavailability or limited systemic exposure, do not significantly impair lactation when used at standard therapeutic doses.

Clinical use in breastfeeding

For breastfeeding women with confirmed C. difficile infection, fidaxomicin may be considered when clinically indicated, as its minimal systemic absorption supports a low level of infant exposure via milk. Some authorities advise a cautious approach—either considering alternative agents with more established lactation data or using fidaxomicin with informed consent—particularly during the early neonatal period or in preterm or medically fragile infants.

Infant monitoring recommendations

When fidaxomicin is used during breastfeeding, routine measurement of infant serum levels is not necessary, but clinical monitoring is prudent. Parents should be advised to observe the infant for gastrointestinal disturbances (diarrhea, constipation, visible blood in stool), feeding difficulties, irritability, or signs of candidiasis (oral thrush or diaper rash) and to seek medical evaluation if such symptoms appear.

Risk–benefit assessment

In mothers with clinically significant C. difficile infection, prompt and effective treatment is essential to reduce morbidity and prevent complications, and the benefits of fidaxomicin may outweigh the theoretical risks to the breastfed infant. When the indication is uncertain or effective alternatives with extensive breastfeeding safety data are available, selecting an agent with better characterized lactation experience may be reasonable, especially for very young or vulnerable infants, while still recognizing the well‑established advantages of maintaining breastfeeding.

Key counselling points

Healthcare professionals should explain that fidaxomicin is taken orally, has minimal systemic absorption, and is therefore unlikely to enter breast milk or the infant circulation in significant amounts, although this has not been directly measured. Shared decision‑making should incorporate the severity of maternal C. difficile infection, the age and health status of the infant, availability of alternative therapies, and the importance of continuing breastfeeding for both maternal and infant health.